About Terapet
Terapet is a company based in Geneve (Switzerland) founded in 2019 by Raymond Miralbell, Marcus palm, and Christina Vallgren. It operates as a HealthTech. Terapet has raised $3.75 million across 12 funding rounds from investors including Eureka Network, Korea Institute for Advancement of Technology (KIAT) and EFI Lake Geneva Ventures. Terapet offers products and services including Qualyscan and Nuclyscan. Terapet operates in a competitive market with competitors including Advanced Oncotherapy, B dot Medical, P-Cure, HIL Medical and Provision Healthcare, among others.
- Headquarter Geneve, Switzerland
- Founders Raymond Miralbell, Marcus palm, Christina Vallgren
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Terapet Sa
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.75 M (USD)
in 12 rounds
-
Latest Funding Round
$1.83 M (USD), Grant
Mar 01, 2024
-
Investors
Eureka Network
& 11 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Terapet
Terapet offers a comprehensive portfolio of products and services, including Qualyscan and Nuclyscan.
An all-in-one solution for proton therapy quality control.
A tool for advancing nuclear imaging technology solutions.
People of Terapet
Unlock access to complete
Unlock access to complete
Funding Insights of Terapet
Terapet has successfully raised a total of $3.75M across 12 strategic funding rounds. The most recent funding activity was a Grant round of $1.83 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Terapet
Terapet has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Eureka Network, Korea Institute for Advancement of Technology (KIAT) and EFI Lake Geneva Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Early-stage startups are accelerated and supported by Fongit in Switzerland.
|
Locked | Locked | Locked |
Investor details for Terapet
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Terapet
Investment portfolio details for Terapet
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Terapet
Detailed financials for Terapet
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Terapet Comparisons
Peer comparison for Terapet
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Terapet
Terapet operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Oncotherapy, B dot Medical, P-Cure, HIL Medical and Provision Healthcare, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of proton beam therapy system for the treatment of cancer
|
|
| Locked | Locked | Locked |
Proton beam therapeutic devices for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Image-guided proton therapy for cancer treatment is provided.
|
|
| Locked | Locked | Locked |
Proton-beam radiotherapy devices are developed for solid tumor treatment.
|
|
| Locked | Locked | Locked |
Proton therapy system for cancer treatment is developed.
|
Detailed competitors of Terapet
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Terapet
Complete news archive for Terapet
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Terapet
Terapet was founded in 2019.
Terapet is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
Christina Vallgren is the current CEO of Terapet. They have also founded this company.
Terapet is a funded company, having raised a total of $3.75M across 12 funding rounds to date.
Terapet SA, based in Geneva, is engaged in creating innovative platform technologies for nuclear medicine and proton therapy. The company is dedicated to advancing imaging solutions through products like Qualyscan and Nuclyscan, which are designed to enhance quality control and clinical nuclear imaging in radiotherapy and precision medicine. Their work is supported by collaborations and aims to position their technologies as primary choices in the medical field.
Terapet's top competitors include Advanced Oncotherapy, P-Cure and HIL Medical.
Terapet offers Qualyscan and Nuclyscan.
Terapet has 12 investors. Key investors include Eureka Network, Korea Institute for Advancement of Technology (KIAT), EFI Lake Geneva Ventures, Nina Capital, and Fongit.